A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment
Latest Information Update: 20 Jun 2023
At a glance
- Drugs EIK 1001 (Primary)
- Indications Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Birdie Biopharmaceuticals; Eikon Therapeutics
- 15 Jun 2023 Status changed from active, no longer recruiting to completed.
- 09 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2021 According to a Seven and Eight Biopharmaceuticals media release, first patient has been treated.